MATT GATLIN: Open Payments
NPI 1629634506 · GULFPORT, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$251 in 12 payments from 5 companies in 2025. Trend: 2023 $678 · 2024 $321 · 2025 $251
Food & beverage: $251
| Company | Payments | Amount |
|---|---|---|
| Melinta Therapeutics, LLC | 5 | $91 |
| Astellas Pharma US Inc | 3 | $71 |
| Gilead Sciences, Inc. | 2 | $54 |
| Merck Sharp & Dohme LLC | 1 | $23 |
| bioMerieux Inc | 1 | $14 |
Products named: Rezzayo, Cresemba, PIFELTRO, FilmArray Meningitis/Encephalitis (ME) Panel.
Industry payments across MS — which companies pay providers there.
